Roswell Park Cancer Institute | GenomeWeb

Roswell Park Cancer Institute

Clinical MDx firm OmniSeq has been an early-access user of the research-use-only assay and is working on validating it to predict checkpoint inhibitor response.

LSU Health New Orleans and OmniSeq will collaborate to offer next-generation sequencing-based tumor profiling services to the institution's oncologists.

The Roswell Park Cancer Institute subsidiary's partnership with Cure Forward will help match patients' tumor profiles to available clinical trials. 

OmniSeq's goal is to make cancer genomic testing available to institutions, including comprehensive cancer centers, oncology practices, and community oncology groups.

NEW YORK (GenomeWeb) – Roswell Park Cancer Institute today said that the New York State Department of Health has granted approval for the institute to test cancer patients using its OmniSeq Target molecular diagnostic test.

NEW YORK (GenomeWeb) – The board of directors of New York State's development agency has approved $105 million in funding to establish the NYS Genomic Medicine and Big Data Center (GMBDC), a genomics data partnership that will connect institutions in Buffalo with the New York Genome Center, Gov.

NEW YORK (GenomeWeb News) – Life Technologies today announced the Ion AmpliSeq Exome Certified Service Provider program and its first members.

NEW YORK (GenomeWeb News) – Roswell Park Cancer Institute is investing $18.5 million to fund the launch of a new Center for Personalized Medicine (CPM) at its campus in Buffalo, according to the office of NY Governor Andrew Cuomo.

New York State plans to fund a two-year, $5.1 million sequencing pilot project of 1,000 residents in Western New York under its Regional Economic Development Council Initiative.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – A Roswell Park Cancer Institute researcher will use a $100,000 award to develop a blood-based test for diagnosing lung cancer.

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.